Moss, 14 February 2020
Gentian Diagnostics AS announces its results for the 4th quarter and 2019 preliminary annual results.
The highlights include:
- Record sales revenues of MNOK 14.1 in 4Q19, up from MNOK 11.1 in 4Q18, totaling a 27 % growth y/y
- Total sales revenue for the year of MNOK 48.0 representing 20 % growth compared to 2018
- Strong fCAL® turbo sales in Q4 resulting in a y/y growth of 112% driven by continued growth in kit sales and positive effect from bulk orders
- fPELA development completed. External validation ongoing
Please find the report and results presentation enclosed here:
14th Feb 2020 - Quarterly Report - Q4
14th Feb 2020 - Quarterly Presentation - Q4
For further information, please contact:
Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 495485
UtstederID: GENT-ME
Marked: Merkur Market